These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 37806342

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian pediatric patients: Real world experience.
    Parra-Izquierdo V, Frías-Ordoñez JS, Cuadros C, Vargas M, Vera Chamorro JF, Romero Sanchez C, Flórez-Sarmiento C.
    Gastroenterol Hepatol; 2024; 47(6):574-581. PubMed ID: 37820832
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience.
    Kotwani P, Terdiman J, Lewin S.
    J Crohns Colitis; 2020 Jul 30; 14(7):1026-1028. PubMed ID: 32020189
    [Abstract] [Full Text] [Related]

  • 5. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study.
    Carvalhas Gabrielli AM, Ferretti F, Monico CM, Tombetti E, Maconi G, Romeo S, Piazza O Sed N, Caprioli F, Mazzola AM, Alicante S, Bertè R, Lolli E, Scribano ML, Buscarini E, Ricci C, Carmagnola S, Ardizzone S, Cannatelli R.
    Dig Dis Sci; 2024 May 30; 69(5):1785-1792. PubMed ID: 38530500
    [Abstract] [Full Text] [Related]

  • 6. Real world evidence on the effectiveness and safety of tofacitinib in ulcerative colitis in Lebanon.
    Sharara AI, Alrazim A, Saniour P, Daniel F, Rached AA, Bahr A, Azar C, Geagea A, Ghoubar M.
    BMC Gastroenterol; 2024 Oct 04; 24(1):349. PubMed ID: 39367371
    [Abstract] [Full Text] [Related]

  • 7. Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study.
    Yoon H, Ye BD, Kang SB, Lee KM, Choi CH, Jo JY, Woo J, Cheon JH.
    BMC Gastroenterol; 2024 Aug 19; 24(1):273. PubMed ID: 39160459
    [Abstract] [Full Text] [Related]

  • 8. Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis.
    Lopes SR, Martins C, Teixeira M, Tomás D.
    World J Gastroenterol; 2024 Sep 14; 30(34):3929-3931. PubMed ID: 39350781
    [Abstract] [Full Text] [Related]

  • 9. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
    Lair-Mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B, Carbonnel F, Peyrin-Biroulet L, Simon M, Viennot S, Bouhnik Y.
    Dig Liver Dis; 2020 Mar 14; 52(3):268-273. PubMed ID: 31732444
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J, OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators.
    N Engl J Med; 2017 May 04; 376(18):1723-1736. PubMed ID: 28467869
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study.
    Ollech JE, Eran-Banai H, Goren I, Sharar Fischler T, Avni-Biron I, Snir Y, Broitman Y, Cohen S, Friedenberg A, Pauker MH, Dotan I, Yanai H.
    Ann Med; 2024 Dec 04; 56(1):2358183. PubMed ID: 38813808
    [Abstract] [Full Text] [Related]

  • 15. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis.
    Kojima K, Watanabe K, Kawai M, Yagi S, Kaku K, Ikenouchi M, Sato T, Kamikozuru K, Yokoyama Y, Takagawa T, Shimizu M, Shinzaki S.
    World J Gastroenterol; 2024 Apr 07; 30(13):1871-1886. PubMed ID: 38659488
    [Abstract] [Full Text] [Related]

  • 16. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
    Weisshof R, Aharoni Golan M, Sossenheimer PH, El Jurdi K, Ollech JE, Pekow J, Cohen RD, Sakuraba A, Dalal S, Rubin DT.
    Dig Dis Sci; 2019 Jul 07; 64(7):1945-1951. PubMed ID: 30734234
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
    Panés J, Su C, Bushmakin AG, Cappelleri JC, Mamolo C, Healey P.
    BMC Gastroenterol; 2015 Feb 05; 15():14. PubMed ID: 25651782
    [Abstract] [Full Text] [Related]

  • 20. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
    Mukherjee A, Hazra A, Smith MK, Martin SW, Mould DR, Su C, Niezychowski W.
    Br J Clin Pharmacol; 2018 Jun 05; 84(6):1136-1145. PubMed ID: 29377257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.